Background-In Saudi Arabia, primary gastrointestinal nonHodgkin's lymphoma (NHL) is common. Recently we have reported one of the largest series of primary gastric (PG) diffuse large B-cell lymphoma (DLCL) This has prompted the analysis of another series of patients with primary intestinal DLCL to depict the clinical features and the outcome of that disease and to compare those with that for PG involvement
Introduction
Extranodal non-Hodgkin's lymphomas (NHL) are lymphomas that arise from tissues other than lymph nodes. Those lymphomas constitute a significant percentage of all NHL ranging from approximately 25% in North America to 30%-48% in Western Europe [1] [2] [3] [4] . In developing countries, however, while the actual occurrence of extranodal NHL is not precisely known, it seems that a higher incidence prevails [5] .
The gastrointestinal tract (GIT) is the most frequent primary extranodal localization accounting for an average of 12% of all NHL and 30%-40% of all extranodal sites [6, 7] , with primary intestinal NHL to account for 21%-54% of all GIT sites [7] [8] [9] [10] In Saudi Arabia, population-based statistics have shown that extranodal NHL represents approximately 30% of all lymphomas and of those almost 40% are of GIT origin, with the intestine to account for one-third of all GIT sites To the best of our knowledge, there have not been published series that restricted the analyses to a relatively large number of patients with primary intestinal NHL of the DLCL histology. This has prompted this report to elucidate the clinical features, the management, and the outcome of 66 patients with this histology. We also provide a concise comparison of the current series with that of 185 patients with primary gastric (PG) NHL of the same histology that we have recently reported [11] .
Patients and methods
Between 1982 and 1999, the medical records and pathologic data of all consecutive adult patients with primary intestinal NHL were retrospectively reviewed Clinical data were retrieved to establish that the intestines were indeed the primary site, l e . the intestine had to be the only or the most massively affected organ, and no former or concurrent lymph node localization of NHL should be present. Only cases showing infiltration of the mucosa of the intestines were included. primary mesenteric lymphomas were excluded also excluded were patients with primary gastric NHL with concurrent intestinal involvement One pathologist (JNM) reviewed the histopathology of all patients In this series, we adopted the REAL histologic Classification [12] Phenotypic studies were performed on formalin-fixed paraffinembedded sections using the avidin-biotin immunoperoxidase technique using a panel of monoclonal antibodies [13] The analysis, however, was restricted to those patients with DLCL without concomitant presence of MALT features
Clinical evaluation
All patients were clinically staged with history and physical examination, routine laboratory studies, chest roentgenogram, GIT series as appropriate, computed tomography of the chest, abdomen, and pelvis, bone marrow aspirate and biopsy, and percutaneous liver biopsy if indicated Cardiac assessment including clinical examination, ECG, and echocardiogram was done routinely for all elderly patients and when otherwise indicated In addition to those staging procedures, patients who underwent surgery had pathological staging Assigning the stage of the disease was based on the principles of Ann Arbor Conference criteria [14] , modified according to the staging classification proposed by the international workshop group in Lugano in 1993 [15] . Approximately one month after the end of the scheduled initial management, patients were restaged to assess response
Definition of response and survival
Complete remission (CR) was defined as the disappearance of all clinical evidence of disease, negative gastric biopsy, and normalization of all laboratory and radiological abnormalities related to the disease for a minimum of four weeks Partial response (PR) was indicated by a decrease of 50% or greater in the sum of the products of the maximum perpendicular diameters of each site of measured lesions, lasting at least four weeks Tumor reduction of less than 50%, transient response of less than one month, or disease progression were considered as no response or progressive disease (NR-PD) Disease progression was indicated by the appearance of new lesions, or by a 25% increase in the size of any preexisting lesion(s)
Overall survival (OS) was measured from the date of diagnosis to death (of any cause) or the date of the last contact with the patient [16] Event-free survival (EFS) was measured from the date of diagnosis to disease progression, relapse, or death only for those attaining CR or PR [16] Data analysis and statistical methods A computerized database was assembled to include patients' characteristics, and all clinical, laboratory, and radiological data Also included were therapy details, response, and outcome We tested various prognostic factors for their unadjusted association with CR in a univanate analysis Variables with a P-value of ^0 10 were included in a stepwise multivanate logistic regression analysis to identify the independent predictors for response [17] OS and EFS were estimated according to the Kaplan-Meier method [18] , and the difference in survival between groups was compared by the log-rank test of MantelCox [19] All tests of significance were two-sided Data analysis was carried out using the BMDP Statistical Software [20] 
Results
Over a 17-year period, 96 patients with primary intestinal NHL were seen at King Faisal Specialist Hospital. Sixty-six patients (69%) had DLCL, while the remaining thrity patients had Burkitt's lymphoma (8 patients), (15) 44 (67) 22 (33) 8 (12) 36 (55) 17 (26) 5 (8) 28(50) 31 (56) 37 (56) 8 (12) 21 (32) 30 (45) 36 (56) 6 (9) 12 (18) 39 (59) 9 (14) a Performance status based on the ECOG criteria [21] b Stage based on Rohatmer [15] MALT (6 patients), small lymphocytic NHL (4 patients), and other histologic subtypes (12 patients). This report focused on the 66 patients with DLCL. Laparotomy confirmed the diagnosis and disease stage in 53 patients (80%).
Patients had a median age of 45 ± 17 years (range 14-84 years), with male female ratio of 2 .1. Table 1 depicts patient and disease characteristics. Abdominal swelling and/or pain were the most frequent symptoms (73%), while intestinal obstruction and intestinal perforation occurred in 15% and 6% of patients, respectively. Of the B symptoms, weight loss was documented in 73% of patients, while fever and night sweats were less common. Performance status was defined according to the ECOG criteria [21] . None of the patients had immunodeficiency states.
Therapy and response
Patients received diverse therapeutic modality (Table 2) . Surgery followed by combination chemotherapy was the most frequently used combined therapeutic approach (65% of patients). Chemotherapy either alone or with combination with other modalities was given to 62 (94%) patients. Twenty-five patients (40%), fourteen (23%), twelve (19%), and three (5%) received CHOP, CHEP-B (E denotes epirubicin), CHOP-B, and COP, respectively. The remaining eight patients had other chemotherapy regimens. None of the patients received high-dose chemotherapy The median number of cycles was 6 
26 (39) 27 (41) 13 (20) 59 (89) 3 (5) 4 (6) 10 (15) 56 (85) 43 (65) 3 (5) 7 (11) [15] (range 3-9). None of the patients had radiotherapy alone, while 10 patients had involved field radiation therapy in combination with other modalities.
Of the 64 patients who received treatment, 49 (76%), 5 (8%), and 10 (16%) attained CR, PR, and NR-PD respectively. In a univanate analysis, only normal LDH, and normal serum albumin (5=30 g/1) were associated with a higher probability of attaining CR. The stepwise logistic regression model, however, failed to identify any factor that can independently predict attaining CR
Overall survival
Over a median (± SD) follow-up of 81 (±21) months for all 66 patients, 32 (48%) were alive and disease-free, 5 (8%) were alive with evidence of disease, and the remaining 29 (44%) were dead of disease progression, or disease and/or therapy-related complications. The median OS was 101 months (Figure 1) , and the predicted 5-and 10-year OS was 58% (± 6%), and 48% (± 7%), respectively Table 3 shows the univanate analysis of the influence of various prognostic factors on OS. As shown in the table, only low serum albumin (<30 g/1) was associated with adverse survival outcome. The NHL International Prognostic Index (IPI) failed to prognosticate survival, with the only significant survival difference noted was that for the superior survival of the lowlntermediate risk group as compared with that for the high-risk patients (P = 0.02) However, on adjustment for the multiple comparisons that difference became insignificant. Also shown was the lack of a favorable effect of multi-modality therapy as compared with single modality approach. The proportional hazards model of Cox was not attempted, as only the level of serum albumin was significant in the univariate analysis.
Disease-free survival
The median EFS for those 54 patients who attained CR or PR has not been reached (Figure 1) , and the predicted 5-and 10-year DFS was 61% (±7%) and 52% (±7%), respectively. We performed univanate analyses to test the influence of various factors on EFS (Table 4 ). Only low serum albumin level was associated with adverse survival outcome. Also shown in Table 4 is the favorable effect of multi-modality therapy as compared with single modality approach on EFS. Again, the proportional hazards model of Cox was not attempted. The unadjusted effect of debulking surgery on OS and EFS was also assessed. Of the 52 patients who had surgery, 33 were alive (63%) as compared with four of 14 (31%) who had no surgery (P = 0.001). On the other hand, of 48 patients who had surgery and achieved CR or PR, 29 (60%) remained event-free as compared with 2 of 6 patients (33%) who did not have surgery (P = 0.08).
Analysis of relapse and salvage therapy
Of the 49 patients who attained CR, 14 (29%) subsequently relapsed. Local relapse only was documented in two patients, distant nodal relapse in six, distant nodal and distant extranodal relapse in two, and local and distant relapse in four. Salvage chemotherapy with or Abbreviation N R -not reached° Performance status based on the ECOG criteria [21] b Stage based on Rohatiner [15] without radiotherapy was offered to 12 patients, and two patients were salvaged with radiotherapy only.
The clinical features and outcome of patients with DLCL primary intestinal origin in the current series were compared with that for 185 adult patients with DLCL of PG site that was recently reported from the same institution over the same period. Table 5 shows that patients with primary intestinal lymphoma compared with those with primary gastric NHL were younger with more obvious males preponderance, less likely to experience B symptoms, have better performance status, and more likely to present with advanced disease. Table 5 also shows that the role of surgery was more dominant in the management of patients with intestinal lymphoma, and that more patients with intestinal lymphoma received combination chemotherapy. The OS of patients with primary intestinal lymphoma, however, was not significantly different from that for patients with PG disease.
Discussion
Primary intestinal NHL is the third most common small intestinal neoplasm after adenocarcinoma and carcinoid tumors. The incidence of the disease is rising particularly among immunocompromised patients [22, 23] . While little is known about the pathogenesis of this disease, patients with celiac disease have a 200-fold increased risk of developing intestinal lymphoma, the so called enteropathy-associated T-cell lymphoma [24] . Moreover, similar to the gastric MALT disease, an association has been established between intestinal MALT and Helicobacter pylori infection [25, 26] .
It is known that the majority of primary intestinal lymphomas are of B-cell lineage and most of these are high-grade tumors [26] . In contrast to other published series, the current report only involved patients with DLCL as defined according to the R.E.A.L. Classification. In the current series, patients with primary intestinal DLCL had a younger median age as compared with that for patients with PG involvement seen at our institution and had the same histology. The younger age at presentation is in agreement with that reported by different groups [10, 27] , but in contrast to the lack of age difference noted in a large population-based study Danish study [7] On the other hand, the ratio of males: females in the current series (2:1) is dissimilar to the less male predilection among patients with PG NHL (1.3:1), however, the male preponderance in the current series is identical to that reported by the Danish group [7] .
The majority of patients had B symptoms mainly weight loss (73%), poor performance status (82%; > 1), and presented with advanced stage (73%; HE or IV). Table 5 showed that those potentially adverse prognostic features were more prevalent among patients with primary intestinal NHL as compared with patients with PG involvement. In concordance with some reports [28] , small intestinal involvement was more frequent than colo-rectal disease. On the other hand, other studies have reported almost equal distribution [8, 9] . None of those studies, however, was restricted to patients with DLCL. In the current study, neither the site of involvement nor the number of sites had significant effect on response or survival.
Eighty percent of patients had surgery either alone or in combination with other modalities mainly chemotherapy with anthracyclines-containing regimens Patients who had surgery had better OS and a suggested benefit in the EFS than those who did not. Published series suggest that the role of surgery in primary intestinal involvement is less controversial as compared with its role in PG NHL. Of a series of 63 patients with localized intestinal NHL, radical tumor resectability was highly significant for survival while the influence of stage was moderately significant [10] . Moreover, among 109 patients with all histologic subtypes reported in the Danish study [7] , surgery in combination with chemotherapy was superior to any other treatment combination in localized disease, and in disseminated cases, chemotherapy alone or in combination with surgery was the treatment modality associated with the highest complete remission and five-year survival. In another recent study, the definitive role of surgery for intestinal NHL other than low-grade MALT lymphomas was also confirmed [29] . Nevertheless, our data and the quoted reports were based on retrospective analyses, and therefore selection bias may account for the favorable effect of surgery. We believe that the role of surgery can be only defined precisely through a prospective randomized study.
In the current series, the combined modality approach, mainly surgery and combination chemotherapy, achieved a better response and improved EFS rate. The influence on OS, however, was not significant. Again, due to the retrospective nature of this report, prudent should be exercised in interpreting the outcome from multi-modality strategy.
In the current series, the 5-and 10-year OS rates were 58% and 48%, respectively On the other hand, the 5-and 10-year EFS rates were 61% and 52%, respectively. Comparing our results with those reported from other series is hindered by the fact that most of the reported survival data were derived from patient populations having various pathologic subtypes. A five-year OS of 24% was reported in patients with low-and high-grade MALT intestinal NHL treated by radical surgical resection [10] , and in other reports the five-year OS rate was about 40%-49% [7, 30, 31] .
The relatively small number of patients in this series perhaps, precluded the emergence of sufficient number of predictors of response or prognostic factors of survival and, therefore, hindered attempts for multivariate analyses. It was of interest, nevertheless, to observe in univariate analysis that low serum albumin had adverse influence on response, OS, and EFS. Low serum albumin may only reflect the extent of intestinal involvement rather than being a biological marker of itself. The prognostic significant of low serum albumin was recently reported among patients with high-grade [32] and folhcular lymphomas [33] . Other studies have shown that presence of B symptoms, older age, and advanced stage correlated aversely with survival of patients with primary intestinal NHL [7, 9] . The prognostic effect of the IPI on OS was not demonstrated in the current report The lack of prognostication of the IPI was predicted, as none of components of the index was significant in the univariate analysis of OS or EFS. It was also interesting to find that neither the site of involvement nor the number of sites had an effect on survival.
Despite showing more prevalence of adverse prognostic factors, patients with primary intestinal NHL in our series had comparable survival to that for patients with PG disease. However, the retrospective nature of both series and the diversity of offered therapy preclude any definitive conclusion. One study has shown that intestinal location compared with gastric involvement had an unfavorable outcome (5-year OS, 24% vs 55%) [10] Likewise, the five-year cause-specific survival was worse for patients with primary intestinal versus those with primary gastric disease (49% vs. 63%) [7] . On the other hand, in a series of 175 patients with GI NHL there was no significant difference between OS of patients with gastric and intestinal involvement [9] . Those controversial results may be partially attributed to the diverse histopathological mix among patients.
In conclusion, this retrospective study of a homogenous cohort of patients with primary intestinal DLCL illustrated the clinical features and the outcome of patients with that disease. Patients, by and large, present with various adverse prognostic features, however, utilizing multimodality approach may account for the attainment of a survival outcome that may be comparable to that achieved in PG lymphomas. In the absence of large prospective and randomized studies, treatment philosophies are mostly based on retrospective analyses from single institutions. Definitive studies that prospectively and randomly compare the outcome of different treatment strategies are warranted.
